Mucormycosis in ICU

Study Overview
=================
Brief Summary
-----------------
Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns. ZygoRéa is a retrospective and multicentric French study aimed to evaluate survival of patients with mucormycosis admitted in ICU at day-28 after admission. This study will also try also to describe the epidemiology of patients admitted in ICU.

Detailed Description
-----------------
Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns. The incidence of Mucormycosis is currently increasing reaching 7% of invasive fungal infections in some immunocompromised patients. Because of its aggressive nature, Mucormycosis is associated with poor survival and high morbidity ; mortality is estimated between 16% and 64% according to different retrospective studies. No study has ever evaluated prognosis of patients with mucormycosis admitted in intensive care units (ICU). ZygoRéa is a retrospective and multicentric French study aimed to evaluate survival of patients with mucormycosis admitted in ICU at day-28 after admission. This study will also try also to describe the epidemiology of patients admitted in ICU and to evaluate the prognosis of different subgroups of patients according to : their clinical characteristics : demographic characteristics, clinical conditions and factors of immunosuppression the characteristics of the fungal infection the treatment strategy the severity of the initial illness, evaluated by severity scores Twenty-one French ICU are currently including more than 45 patients.

Official Title
-----------------
Mucormycosis in ICU: A French Multicenter Cohort Study

Conditions
-----------------
Mucormycosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: confirmed or suspected mucormycosis, based on international definition from EORTC/MSG patient hospitalized in intensive care unit during the 2008-2016 period Zygomycosis identification in at least 2 solids organs or identification in hemoculture Exclusion Criteria: Age under 18 years old Patient under the law

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality at Day 28 | Mortality at Day 28 after ICU admission | up to 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality at Day 90 | Mortality at Day 90 after ICU admission | up to 90 days | 
| Mortality during the ICU stage | Mortality status (alive or dead) at the end of the ICU stage | up to 28 days | 
| Length stay in ICU | number of days in intensive care Unit | up to 28 days | 
| Length stay of hospitalization | number of days in hospital | up to 90 days | 
| Mortality during the hospitalization | Mortality status (alive or dead) at the end of the hospitalization | up to 90 days | 
| Prognostic criteria | Prognostic factors of mortality in intensive care units | up to 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mucormycosis, Intensive Care Medicine